Anemia of inflammation

Hematology/Oncology Clinics of North America

Volumn 28, Issue 4, 2014, Pages 671-681

  Nemeth, Elizabeta ^a   Ganz, Tomas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia of chronic disease; Cytokines; Erythropoiesis stimulating agents; Ferroportin; Hepcidin

Indexed keywords

ANTIANEMIC AGENT; C REACTIVE PROTEIN; ERYTHROPOIETIN; FERROPORTIN; GAMMA INTERFERON; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 1; INTERLEUKIN 4; TRANSFERRIN;

ANEMIA; ANEMIA IN INFLAMMATION; DIET SUPPLEMENTATION; ERYTHROCYTE LIFESPAN; ERYTHROCYTE TRANSFUSION; ERYTHROPHAGOCYTOSIS; ERYTHROPOIESIS; EXPERIMENTAL THERAPY; FERRITIN BLOOD LEVEL; HUMAN; INFLAMMATION; IRON BLOOD LEVEL; IRON INTAKE; IRON RESTRICTION; IRON STORAGE; IRON THERAPY; MACROPHAGE; MACROPHAGE ACTIVATION; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; TRANSFERRIN BLOOD LEVEL; URINARY EXCRETION; COMPLICATION;

ANEMIA; HUMANS; INFLAMMATION;

EID: 84904746883     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2014.04.005     Document Type: Review

References (64)

1. Cartwright G.E., Lee G.R. The anaemia of chronic disorders. Br J Haematol 1971, 21(2):147-152.
2. Katz J.H. Iron and protein kinetics studied by means of doubly labeled human crystalline transferrin. J Clin Invest 1961, 40:2143-2152.
3. Corwin H.L., Krantz S.B. Anemia of the critically ill: "acute" anemia of chronic disease. Crit Care Med 2000, 28(8):3098-3099.
4. Beghe C., Wilson A., Ershler W.B. Prevalence and outcomes of anemia in geriatrics: a systematic review of the literature. Am J Med 2004, 116(7 Suppl 1):3-10.
5. Elliott J., Mishler D., Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis 2009, 16(2):94-100.
6. Barron B.A., Hoyer J.D., Tefferi A. A bone marrow report of absent stainable iron is not diagnostic of iron deficiency. Ann Hematol 2001, 80(3):166-169.
7. Krause J.R., Brubaker D., Kaplan S. Comparison of stainable iron in aspirated and needle-biopsy specimens of bone marrow. Am J Clin Pathol 1979, 72(1):68-70.
8. Thomason R.W., Lavelle J., Nelson D., et al. Parenteral iron therapy is associated with a characteristic pattern of iron staining on bone marrow aspirate smears. Am J Clin Pathol 2007, 128(4):590-593.
9. Ferraro S., Mozzi R., Panteghini M. Revaluating serum ferritin as a marker of body iron stores in the traceability era. Clin Chem Lab Med 2012, 50(11):1911-1916.
10. Cozzi A., Santambrogio P., Privitera D., et al. Human L-ferritin deficiency is characterized by idiopathic generalized seizures and atypical restless leg syndrome. J Exp Med 2013, 210(9):1779-1791.
11. Tran T.N., Eubanks S.K., Schaffer K.J., et al. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 1997, 90(12):4979-4986.
12. Thomson A.M., Cahill C.M., Cho H.H., et al. The Acute Box cis-Element in Human Heavy Ferritin mRNA 5'-Untranslated Region Is a Unique Translation Enhancer That Binds Poly(C)-binding Proteins. J Biol Chem 2005, 280(34):30032-30045.
13. Cohen L.A., Gutierrez L., Weiss A., et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood 2010, 116(9):1574-1584.
14. Cazzola M., Ponchio L., de Benedetti F., et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996, 87(11):4824-4830.
15. Cook J.D., Flowers C.H., Skikne B.S. The quantitative assessment of body iron. Blood 2003, 101(9):3359-3363.
16. Pettersson T., Kivivuori S.M., Siimes M.A. Is serum transferrin receptor useful for detecting iron-deficiency in anaemic patients with chronic inflammatory diseases?. Br J Rheumatol 1994, 33(8):740-744.
17. Skikne B.S., Flowers C.H., Cook J.D. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood 1990, 75(9):1870-1876.
18. Infusino I., Braga F., Dolci A., et al. Soluble transferrin receptor (sTfR) and sTfR/log ferritin index for the diagnosis of iron-deficiency anemia a meta-analysis. Am J Clin Pathol 2012, 138(5):642-649.
19. Litton E., Xiao J., Ho K.M. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ 2013, 347:f4822.
20. Freireich E.J., Ross J.F., Bayles T.B., et al. Radioactive iron metabolism and erythrocyte survival studies of the mechanism of the anemia associated with rheumatoid arthritis. J Clin Invest 1957, 36(7):1043-1058.
21. Troutt J.S., Butterfield A.M., Konrad R.J. Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates. J Clin Lab Anal 2013, 27(6):504-510.
22. Correll C.K., Binstadt B.A. Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis. Pediatr Res 2014, 75(1-2):176-183.
23. Milner J.D., Orekov T., Ward J.M., et al. Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulation. Blood 2010, 116(14):2476-2483.
24. Libregts S.F., Gutierrez L., de Bruin A.M., et al. Chronic IFN-gamma production in mice induces anemia by reducing erythrocyte life span and inhibiting erythropoiesis through an IRF-1/PU.1 axis. Blood 2011, 118(9):2578-2588.
25. Ganz T. Systemic iron homeostasis. Physiol Rev 2013, 93(4):1721-1741.
26. Ganz T., Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012, 1823(9):1434-1443.
27. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004, 306(5704):2090-2093.
28. Nemeth E., Rivera S., Gabayan V., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113(9):1271-1276.
29. Rodriguez R., Jung C.L., Gabayan V., et al. Hepcidin induction by pathogens and pathogen-derived molecules is strongly dependent on interleukin-6. Infect Immun 2014, 82(2):745-752.
30. Kemna E., Pickkers P., Nemeth E., et al. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005, 106(5):1864-1866.
31. Nicolas G., Chauvet C., Viatte L., et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002, 110(7):1037-1044.
32. Finberg K.E., Heeney M.M., Campagna D.R., et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet 2008, 40(5):569-571.
33. Finberg K.E. Iron-refractory iron deficiency anemia. Semin Hematol 2009, 46(4):378-386.
34. Camaschella C., Poggiali E. Inherited disorders of iron metabolism. Curr Opin Pediatr 2011, 23(1):14-20.
35. Du X., She E., Gelbart T., et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science 2008, 320(5879):1088-1092.
36. Silvestri L., Pagani A., Nai A., et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008, 8(6):502-511.
37. Means R.T., Krantz S.B. Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest 1993, 91(2):416-419.
38. Means R.T., Dessypris E.N., Krantz S.B. Inhibition of human erythroid colony-forming units by interleukin-1 is mediated by gamma interferon. J Cell Physiol 1992, 150(1):59-64.
39. Means R.T., Krantz S.B. Inhibition of human erythroid colony-forming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 1991, 78(10):2564-2567.
40. Broxmeyer H.E., Williams D.E., Lu L., et al. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. J Immunol 1986, 136(12):4487-4495.
41. Felli N., Pedini F., Zeuner A., et al. Multiple members of the TNF superfamily contribute to IFN-γmediated inhibition of erythropoiesis. J Immunol 2005, 175(3):1464-1472.
42. Johnson R.A., Waddelow T.A., Caro J., et al. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989, 74(1):130-138.
43. Richardson C.L., Delehanty L.L., Bullock G.C., et al. Isocitrate ameliorates anemia by suppressing the erythroid iron restriction response. J Clin Invest 2013, 123(8):3614-3623.
44. Sasu B.J., Cooke K.S., Arvedson T.L., et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 2010, 115(17):3616-3624.
45. Gardenghi S., Renaud T.M., Meloni A., et al. Distinct roles for hepcidin and interleukin-6 in the recovery from anemia in mice injected with heat-killed Brucella abortus. Blood 2014, 123(8):1137-1145.
46. Kim A., Fung E., Parikh S.G., et al. A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin. Blood 2014, 123(8):1129-1136.
47. Cooke K.S., Hinkle B., Salimi-Moosavi H., et al. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood 2013, 122(17):3054-3061.
48. Theurl I., Schroll A., Sonnweber T., et al. Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats. Blood 2011, 118(18):4977-4984.
49. Kato Y., Takagi C., Tanaka J., et al. Effect of daily subcutaneous administration of recombinant erythropoietin on chronic anemia in rheumatoid arthritis. Intern Med 1994, 33(4):193-197.
50. Peeters H.R., Jongen-Lavrencic M., Bakker C.H., et al. Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatol Int 1999, 18(5-6):201-206.
51. Peeters H.R., Jongen-Lavrencic M., Vreugdenhil G., et al. Effect of recombinant human erythropoietin on anaemia and disease activity in patients with rheumatoid arthritis and anaemia of chronic disease: a randomised placebo controlled double blind 52 weeks clinical trial. Ann Rheum Dis 1996, 55(10):739-744.
52. Pettersson T., Rosenlof K., Friman C., et al. Successful treatment of the anemia of rheumatoid arthritis with subcutaneously administered recombinant human erythropoietin. Slower response in patients with more severe inflammation. Scand J Rheumatol 1993, 22(4):188-193.
53. Arndt U., Kaltwasser J.P., Gottschalk R., et al. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin. Ann Hematol 2005, 84(3):159-166.
54. Singh A. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence. Semin Dial 2009, 22(1):64-69.
55. Song S.N., Tomosugi N., Kawabata H., et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 2010, 116(18):3627-3634.
56. Song S.N., Iwahashi M., Tomosugi N., et al. Comparative evaluation of the effects of treatment with tocilizumab and TNF-alpha inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res Ther 2013, 15(5):R141.
57. Isaacs J.D., Harari O., Kobold U., et al. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther 2013, 15(6):R204.
58. Schipperus M., Rijnbeek B., Reddy M., et al. CNTO328 (Anti-IL-6 mAb) treatment is associated with an increase in hemoglobin (Hb) and decrease in hepcidin levels in renal cell carcinoma (RCC). Blood 2009, 22(114):4045. [abstract].
59. Hohlbaum A., Gille H., Christian J., et al. Iron mobilization and pharmacodynic marker measurements in non-human primates following administration of PRS-080, a novel and highly specific anti-hepcidin therapeutic. Am J Hematol 2013, 88(5):E41. [abstract].
60. Schwoebel F., van Eijk L.T., Zboralski D., et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood 2013, 121(12):2311-2315.
61. Steinbicker A.U., Sachidanandan C., Vonner A.J., et al. Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood 2011, 117(18):4915-4923.
62. Poli M., Girelli D., Campostrini N., et al. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood 2011, 117(3):997-1004.
63. Crosby J.R., Gaarde W.A., Egerston J., et al. Targeting hepcidin with antisense oligonucletides improves anemia endpoints in mice. Blood 2006, 108(11 Pt 1):83A-84A.
64. Akinc A., Chan-Daniels A., Sehgal A., et al. Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia. Blood 2011, 118(21):315.